Weight loss when switching the treatment from insulin to dulaglutide

Scientists have carried out a retrospective review of electronic health records of patients with type 2 diabetes who were switched from insulin to dulaglutide. The study involved 98 patients switched from insulin to dulaglutide, and continued dulaglutide therapy for at least 6 months. Previously, 94 of them were treated with a combination of insulin and an oral antidiabetic agent.

Based on the obtained data, adults with type 2 diabetes had a low level of HbA1c (glycated hemoglobin), and experienced body weight loss 6 months after switching the treatment from insulin to GLP-1 receptor agonist dulaglutide. The researchers say that a higher baseline HbA1c level was an independent predictor of a glucose-lowering response to dulaglutide in this group of patients. Patients who received short- and long-acting insulin had an average weight loss of 3.69 kg compared to an average weight loss of 1.25 kg in those who received only long-acting insulin.

Source: healio